mP-CSE (827858)

  https://cordis.europa.eu/project/id/827858

  Horizon 2020 (2014-2020)

  Micro-physiological circadian platform for safety and efficacy assessment of drugs and cosmetics

  SME instrument (EIC-SMEInst-2018-2020)

  drug discovery  ·  drug safety  ·  pharmaceutical drugs  ·  organ on a chip

  2018-08-01 Start Date (YY-MM-DD)

  2018-11-30 End Date (YY-MM-DD)

  € 71,429 Total Cost

  Description

Tissue Dynamics Ltd. is a groundbreaking biotechnology company focused on developing smart microphysiological platform technologies for drug, food, and cosmetic development. Pharmaceutical and cosmetic companies face huge costs of developing and testing new products (an average of €2.5B to develop a single drug), which is increasing over the years. Traditionally, these tests have been carried out in animal models whose limitations in predicting human responses are significant (70% of drugs toxic to humans are not toxic to animals). These limitations lead to the withdrawal of many drugs in the market, making drug development a costly risky process. Organ-on-chip platforms, developed in recent years, have proven to be a better alternative to current laboratory models, offering more physiological and similar characteristics to the human body. Tissue Dynamics goal is to provide a functionally scaled Multi Organ-on-Chip (MOC) platform that uses real-time sensing of tissue function to detect the effect of drug-induced physiological stress in multiple 3D vascular organs (liver, heart, brain, kidney). Our latest innovation has been the incorporation of factors that mimic circadian rhythms in the organs, which is essential to test the physiological impact of the compounds tested. On the other hand, the incorporation of the circadian rhythm in our chips enhances the development of treatment schemes, adjusting in a more precise way the dose and the time of administration of the medications, seeking the maximum efficacy of them. The global Organ-on-Chip market is a rapidly-growing, estimated to reach $6.13 Billion by 2025, with an expected growth rate of CAGR 69.4%. Our platform will reduce the cost of new drugs development ultimately, helping patients by making more safe and effective medicines reach the market. In turn we expect ROI of 5 after five years of commercialization and hire 10 new employees.

  Complicit Organisations

1 Israeli organisation participates in mP-CSE.